Pancreatic Cancer Research

ResearcherUniversity Medical Center of the Johannes Gutenberg University MainzActive in the last 2 years

Stefan Heinrich

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9961-0957; OpenAlex author ID A5066597159. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 13

  1. Aberrant Expression of A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) in Pancreatic Cancer Leads to Dichotomic Functions. Co-author DOI 10.1002/mco2.70462↗
  2. Stress Granules Determine the Development of Obesity-Associated Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-21-1672↗
  3. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  4. Why surgeons care about systemic chemotherapy for pancreatic cancer? Co-author DOI 10.21037/hbsn-21-398↗
  5. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  6. Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging in Pancreatic Cancer is Associated with Tumor Hypoxia. Co-author DOI 10.3390/cancers13010089↗
  7. [Lymphadenectomy in oncological visceral surgery-Part 1 : Hepatobiliary tumors and pancreatic cancer]. First author DOI 10.1007/s00104-019-0956-7↗
  8. Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2019.06.006↗
  9. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Co-author DOI 10.1186/s12885-019-5889-5↗
  10. Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection? Co-author DOI 10.21037/hbsn.2018.03.11↗
  11. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Co-author DOI 10.3390/ijms18081622↗
  12. Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.5754/hge11805↗
  13. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthias M. Gaida · 4 shared papers, 2020–2025 · strength 0.58
  2. Hauke Lang · 4 shared papers, 2011–2019 · strength 0.40
  3. Philipp Mayer · 2 shared papers, 2020–2025 · strength 0.33
  4. Stephanie Allmang · 1 shared paper, 2025 · strength 0.23
  5. Mickaël Lesurtel · 3 shared papers, 2011–2021 · strength 0.21
  6. Edward S. Sim · 1 shared paper, 2022 · strength 0.17
  7. Alexandra Redding · 1 shared paper, 2022 · strength 0.17
  8. Guillaume Fonteneau · 1 shared paper, 2022 · strength 0.17
  9. Elda Grabocka · 1 shared paper, 2022 · strength 0.17
  10. F. Bartsch · 1 shared paper, 2019 · strength 0.14
  11. Markus Hermann Moehler · 2 shared papers, 2011–2019 · strength 0.12
  12. Pierre‐Alain Clavien · 2 shared papers, 2011–2021 · strength 0.11
  13. Miriam Klauß · 1 shared paper, 2020 · strength 0.10
  14. Thilo Hackert · 1 shared paper, 2020 · strength 0.10
  15. Jean‐Luc Van Laethem · 1 shared paper, 2019 · strength 0.09
  16. Manfred Paul Lutz · 1 shared paper, 2019 · strength 0.09
  17. Marc G. Besselink · 1 shared paper, 2019 · strength 0.09
  18. Michel Pierre Ducreux · 1 shared paper, 2019 · strength 0.09
  19. Michelle Lucinda DeOliveira · 1 shared paper, 2021 · strength 0.09
  20. Carla Serra · 1 shared paper, 2021 · strength 0.09
  21. Saskia Hussung · 1 shared paper, 2021 · strength 0.09
  22. Riccardo Casadei · 1 shared paper, 2021 · strength 0.09
  23. Carlo Ingaldi · 1 shared paper, 2021 · strength 0.09
  24. Mariacristina Di Marco · 1 shared paper, 2021 · strength 0.09
  25. Dominique Lisa Birrer · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.